Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRNX
stocks logo

CRNX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.364
+55%
--
--
-1.411
+35.7%
--
--
-1.405
+14.23%
Estimates Revision
The market is revising Downward the revenue expectations for Crinetics Pharmaceuticals, Inc. (CRNX) for FY2025, with the revenue forecasts being adjusted by -9.19% over the past three months. During the same period, the stock price has changed by 33.16%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.12%
In Past 3 Month
Stock Price
Go Up
up Image
+33.16%
In Past 3 Month
Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 80.00 USD with a low forecast of 45.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 80.00 USD with a low forecast of 45.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.420
sliders
Low
45.00
Averages
80.00
High
108.00
Current: 47.420
sliders
Low
45.00
Averages
80.00
High
108.00
Goldman Sachs
Neutral
maintain
$40 -> $45
2025-11-10
Reason
Goldman Sachs
Price Target
$40 -> $45
2025-11-10
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Crinetics to $45 from $40 and keeps a Neutral rating on the shares.
Citizens JMP
Jonathan Wolleben
Outperform
downgrade
$143 -> $108
2025-11-07
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$143 -> $108
2025-11-07
downgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Crinetics to $108 from $143 and keeps an Outperform rating on the shares. Crinetics has hit the ground running following Palsonify's approval in late September, with the first revenue coming in January, which will help set expectations for the launch curve, the analyst tells investors in a research note.
Oppenheimer
Outperform
maintain
$73 -> $87
2025-09-30
Reason
Oppenheimer
Price Target
$73 -> $87
2025-09-30
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Crinetics to $87 from $73 and keeps an Outperform rating on the shares. The firm has made revisions to its Crinetics model following Palsonify's FDA approval for acromegaly. Oppenheimer now projects 2026-2028 global Palsonify sales of $60M, 214M, and 419M vs. Visible Alpha consensus of $54M, 166M, and 300M.
Stifel
NULL -> Buy
maintain
$58 -> $75
2025-09-29
Reason
Stifel
Price Target
$58 -> $75
2025-09-29
maintain
NULL -> Buy
Reason
Stifel raised the firm's price target on Crinetics to $75 from $58 and keeps a Buy rating on the shares after updating the firm's model following last week's approval of Palsonify in acromegaly. The price point of $290,000 per year came in well-above expectations of parity to a marginal premium to standard-of-care SRLs and improves the set-up, the analyst tells investors.
Morgan Stanley
NULL -> Overweight
maintain
$65 -> $77
2025-09-28
Reason
Morgan Stanley
Price Target
$65 -> $77
2025-09-28
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Crinetics to $77 from $65 and keeps an Overweight rating on the shares. The FDA approval of Palsonify cam with a better than expected list price and "broad" label, the analyst tells investors in a research note. The firm believes the drug is positioned to address a significant unmet need for a once-daily oral option across patient segments.
Citizens JMP
Jonathan Wolleben
Outperform
upgrade
$86 -> $143
2025-09-26
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$86 -> $143
2025-09-26
upgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on Crinetics to $143 from $86 and keeps an Outperform rating on the shares. The firm says Palsonify is now approved to treat acromegaly with a "clean label." A leading endocrinologist expects the only once daily oral option to "corner the market" as a "once in a lifetime drug," the analyst tells investors in a research note. The firm says the rare disease opportunity has blockbuster potential at Palsonify's pricing with the 11,500 actively managed U.S. patients represents over a $3B total addressable market.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX.O) is -8.49, compared to its 5-year average forward P/E of -8.08. For a more detailed relative valuation and DCF analysis to assess Crinetics Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.08
Current PE
-8.49
Overvalued PE
-5.24
Undervalued PE
-10.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.53
Undervalued EV/EBITDA
-8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
939.52
Current PS
0.00
Overvalued PS
2193.92
Undervalued PS
-314.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 448.61% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRNX News & Events

Events Timeline

(ET)
2025-12-03
08:20:00
Crinetics Doses First Patient in CRN09682 Phase 1/2 Study
select
2025-11-20 (ET)
2025-11-20
16:11:42
Crinetics Enrolls First Patient in CAREFNDR Trial
select
2025-11-06 (ET)
2025-11-06
17:57:32
Crinetics announces Q3 EPS of $1.38, surpassing consensus estimate of $1.25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Newsfilter
PinnedCrinetics Doses First Patient in Phase 1/2 Study of CRN09682 for SST2-Positive Tumors
  • Clinical Trial Launch: Crinetics Pharmaceuticals has successfully dosed the first patient in its Phase 1/2 study of CRN09682, marking a significant milestone in providing potentially more effective and safer targeted therapy for patients with metastatic or locally advanced SST2-positive neuroendocrine tumors.
  • Innovative Drug Platform: CRN09682 is the lead candidate from Crinetics' proprietary nonpeptide drug conjugate (NDC) platform, designed to enhance treatment efficacy by optimizing tumor penetration and minimizing systemic exposure, which could transform the treatment landscape for neuroendocrine tumors.
  • Trial Scale and Design: The BRAVESST2 trial plans to enroll up to 150 patients using an open-label, dose-escalation design aimed at evaluating the safety, tolerability, and preliminary anti-tumor activity of CRN09682, further advancing its clinical development.
  • Market Potential: With increasing demand for targeted therapies for SST2-expressing tumors, the successful development of CRN09682 could present significant market opportunities for Crinetics, particularly in the neuroendocrine tumor treatment space, likely attracting more investment and attention.
[object Object]
Preview
9.0
11-21NASDAQ.COM
Crinetics Launches Phase 3 Study of Paltusotine for New Use in Carcinoid Syndrome

  • Crinetics Pharmaceuticals Initiates Phase 3 Trial: Crinetics Pharmaceuticals has launched its pivotal Phase 3 trial, CAREFNDR, for Paltusotine in adults with carcinoid syndrome, aiming to improve quality of life for patients suffering from symptoms like flushing and diarrhea.

  • Trial Design and Objectives: The multicenter, randomized, double-blind trial will enroll 141 adults to assess the efficacy of Paltusotine compared to a placebo over 16 weeks, focusing on changes in flushing episodes and bowel movement frequency.

  • Paltusotine's Current Approval and Future Goals: Paltusotine, already approved for acromegaly treatment under the brand name PALSONIFY, is being explored for broader applications, with Crinetics aiming to expand its use beyond its initial indication.

  • Financial Position and Upcoming Milestones: Crinetics reported a cash balance of $1.1 billion as of September 30, 2025, which will support its operations through 2029, while also planning additional studies for other treatments in the coming years.

[object Object]
Preview
9.5
11-07NASDAQ.COM
Crinetics Pharmaceuticals Inc Reports Larger Q3 Loss, Falling Short of Expectations

  • Quarterly Loss Report: Crinetics Pharmaceuticals Inc reported a third-quarter loss of $130.09 million, or $1.38 per share, which is an increase from a loss of $76.83 million, or $0.96 per share, in the same period last year.

  • Analyst Expectations: The reported loss exceeded analysts' expectations, who had anticipated a loss of $1.25 per share, indicating a significant shortfall in performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Crinetics Pharmaceuticals Inc (CRNX) stock price today?

The current price of CRNX is 47.42 USD — it has increased 0.94 % in the last trading day.

arrow icon

What is Crinetics Pharmaceuticals Inc (CRNX)'s business?

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

arrow icon

What is the price predicton of CRNX Stock?

Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 80.00 USD with a low forecast of 45.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Crinetics Pharmaceuticals Inc (CRNX)'s revenue for the last quarter?

Crinetics Pharmaceuticals Inc revenue for the last quarter amounts to 143.00K USD, decreased % YoY.

arrow icon

What is Crinetics Pharmaceuticals Inc (CRNX)'s earnings per share (EPS) for the last quarter?

Crinetics Pharmaceuticals Inc. EPS for the last quarter amounts to -1.38 USD, increased 43.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Crinetics Pharmaceuticals Inc (CRNX)'s fundamentals?

The market is revising Downward the revenue expectations for Crinetics Pharmaceuticals, Inc. (CRNX) for FY2025, with the revenue forecasts being adjusted by -9.19% over the past three months. During the same period, the stock price has changed by 33.16%.
arrow icon

How many employees does Crinetics Pharmaceuticals Inc (CRNX). have?

Crinetics Pharmaceuticals Inc (CRNX) has 437 emplpoyees as of December 05 2025.

arrow icon

What is Crinetics Pharmaceuticals Inc (CRNX) market cap?

Today CRNX has the market capitalization of 4.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free